France
Cible Skin, founded by Drs. Joël and Raphaël Aknin in 2020, is poised at the forefront of dermatological and longevity innovation, headquartered in France. The company’s slogan, "Reversing skin aging through immune resilience. 1-LGVTY®: Cible Skin’s patented longevity technology," encapsulates its groundbreaking mission in skincare technology.
At the core of Cible Skin's breakthrough offerings is 1-LGVTY®, a patented biotechnology characterized by its ability to reverse skin aging at a cellular level. Unlike traditional cosmetic approaches that focus merely on skin appearance, this technology actively reduces the skin’s biological age, enhancing regeneration and resilience by engaging the skin’s immune ecosystem.
The company recently secured funding from Verlinvest in a Private Equity Round on 08 February 2024, underscoring strong investor confidence in its innovative trajectory at the intersection of medicine, longevity science, and dermatology.
